This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rempel, S. A. Articles by Gutiérrez, J. A. Search for Related Content PubMed PubMed Citation Articles by Rempel, S. A. Articles by Gutiérrez, J. A.

SPARC: A Potential Diagnostic Marker of Invasive Meningiomas¹

Henry Ford Midwest Neuro-Oncology Center and the Departments of Neurosurgery [S. A. R., S. G.] and Pathology [J. A. G.], Henry Ford Health Sciences Center, Detroit, Michigan 48202

SPARC, a secreted, extracellular matrix-associated protein implicated in the modulation of cell adhesion and migration, was evaluated as a marker for invasive meningiomas. Although the majority of meningiomas are clinically and morphologically benign, 10% progress into atypical and malignant tumors, according to the standard criteria. However, a subset of meningiomas presents as histomorphologically benign tumors (WHO grade I), but they are clinically invasive. It has been suggested that these tumors should be classified as malignant, and that the patients may require adjuvant therapy and closer follow up. Unfortunately, a significant number of these tumors may not be recognized because the surgical specimen used to assess the grade of a tumor lacks the infiltrative interface with the brain, which is currently necessary to determine its invasive character. Therefore, a marker of heightened invasiveness would greatly facilitate the identification of this subset of patients. In this study, the immunohistochemical expression of SPARC in benign, noninvasive primary meningiomas was compared with its expression in invasive, aggressive, primary and recurrent meningiomas. SPARC was not expressed in the 9 benign, noninvasive tumors, but was highly expressed in the 20 invasive tumors, regardless of the grade. The findings suggest that SPARC is a potential diagnostic marker of invasive meningiomas and is capable of distinguishing the histomorphologically benign noninvasive from the histomorphologically benign but invasive meningiomas, in the absence of the infiltrative interface.

This article has been cited by other articles:

				H. Okamoto, J. Li, A. O. Vortmeyer, H. Jaffe, Y.-S. Lee, S. Glasker, T.-S. Sohn, W. Zeng, B. Ikejiri, M. A. Proescholdt, et al. Comparative proteomic profiles of meningioma subtypes. Cancer Res., October 15, 2006; 66(20): 10199 - 10204. [Abstract] [Full Text] [PDF]

				Y. Ikuta, T. Nakatsura, T. Kageshita, S. Fukushima, S. Ito, K. Wakamatsu, H. Baba, and Y. Nishimura Highly Sensitive Detection of Melanoma at an Early Stage Based on the Increased Serum Secreted Protein Acidic and Rich in Cysteine and Glypican-3 Levels Clin. Cancer Res., November 15, 2005; 11(22): 8079 - 8088. [Abstract] [Full Text] [PDF]

				D. W. Nyman, K. J. Campbell, E. Hersh, K. Long, K. Richardson, V. Trieu, N. Desai, M. J. Hawkins, and D. D. Von Hoff Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies J. Clin. Oncol., November 1, 2005; 23(31): 7785 - 7793. [Abstract] [Full Text] [PDF]

				M. J. Alvarez, F. Prada, E. Salvatierra, A. I. Bravo, V. P. Lutzky, C. Carbone, F. J. Pitossi, H. E. Chuluyan, and O. L. Podhajcer Secreted Protein Acidic and Rich in Cysteine Produced by Human Melanoma Cells Modulates Polymorphonuclear Leukocyte Recruitment and Antitumor Cytotoxic Capacity Cancer Res., June 15, 2005; 65(12): 5123 - 5132. [Abstract] [Full Text] [PDF]

				J. N. Rich, C. Hans, B. Jones, E. S. Iversen, R. E. McLendon, B.K. A. Rasheed, A. Dobra, H. K. Dressman, D. D. Bigner, J. R. Nevins, et al. Gene Expression Profiling and Genetic Markers in Glioblastoma Survival Cancer Res., May 15, 2005; 65(10): 4051 - 4058. [Abstract] [Full Text] [PDF]

				A. Chlenski, S. Liu, L. J. Baker, Q. Yang, Y. Tian, H. R. Salwen, and S. L. Cohn Neuroblastoma Angiogenesis Is Inhibited with a Folded Synthetic Molecule Corresponding to the Epidermal Growth Factor-Like Module of the Follistatin Domain of SPARC Cancer Res., October 15, 2004; 64(20): 7420 - 7425. [Abstract] [Full Text] [PDF]

				M. W.M. Schellings, Y. M. Pinto, and S. Heymans Matricellular proteins in the heart: possible role during stress and remodeling Cardiovasc Res, October 1, 2004; 64(1): 24 - 31. [Abstract] [Full Text] [PDF]

				S. Chevillard, N. Ugolin, P. Vielh, K. Ory, C. Levalois, D. Elliott, G. L. Clayman, and A. K. El-Naggar Gene Expression Profiling of Differentiated Thyroid Neoplasms: Diagnostic and Clinical Implications Clin. Cancer Res., October 1, 2004; 10(19): 6586 - 6597. [Abstract] [Full Text] [PDF]

				P. A. Puolakkainen, R. A. Brekken, S. Muneer, and E. H. Sage Enhanced Growth of Pancreatic Tumors in SPARC-Null Mice Is Associated With Decreased Deposition of Extracellular Matrix and Reduced Tumor Cell Apoptosis Mol. Cancer Res., April 1, 2004; 2(4): 215 - 224. [Abstract] [Full Text] [PDF]

				S. Sangaletti, A. Stoppacciaro, C. Guiducci, M. R. Torrisi, and M. P. Colombo Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma J. Exp. Med., November 17, 2003; 198(10): 1475 - 1485. [Abstract] [Full Text] [PDF]

				J. N. Rich, Q. Shi, M. Hjelmeland, T. J. Cummings, C.-T. Kuan, D. D. Bigner, C. M. Counter, and X.-F. Wang Bone-related Genes Expressed in Advanced Malignancies Induce Invasion and Metastasis in a Genetically Defined Human Cancer Model J. Biol. Chem., April 25, 2003; 278(18): 15951 - 15957. [Abstract] [Full Text] [PDF]

				A. Chlenski, S. Liu, S. E. Crawford, O. V. Volpert, G. H. DeVries, A. Evangelista, Q. Yang, H. R. Salwen, R. Farrer, J. Bray, et al. SPARC Is a Key Schwannian-derived Inhibitor Controlling Neuroblastoma Tumor Angiogenesis Cancer Res., December 15, 2002; 62(24): 7357 - 7363. [Abstract] [Full Text] [PDF]

				C. Schultz, N. Lemke, S. Ge, W. A. Golembieski, and S. A. Rempel Secreted Protein Acidic and Rich in Cysteine Promotes Glioma Invasion and Delays Tumor Growth in Vivo Cancer Res., November 1, 2002; 62(21): 6270 - 6277. [Abstract] [Full Text] [PDF]

				R. A. Sturm, K. Satyamoorthy, F. Meier, B. B. Gardiner, D. J. Smit, B. Vaidya, and M. Herlyn Osteonectin/SPARC Induction by Ectopic {beta}3 Integrin in Human Radial Growth Phase Primary Melanoma Cells Cancer Res., January 1, 2002; 62(1): 226 - 232. [Abstract] [Full Text] [PDF]

				G. K. Yiu, W. Y. Chan, S.-W. Ng, P. S. Chan, K. K. Cheung, R. S. Berkowitz, and S. C. Mok SPARC (Secreted Protein Acidic and Rich in Cysteine) Induces Apoptosis in Ovarian Cancer Cells Am. J. Pathol., August 1, 2001; 159(2): 609 - 622. [Abstract] [Full Text]

				H. Huang, S. Colella, M. Kurrer, Y. Yonekawa, P. Kleihues, and H. Ohgaki Gene Expression Profiling of Low-Grade Diffuse Astrocytomas by cDNA Arrays Cancer Res., December 1, 2000; 60(24): 6868 - 6874. [Abstract] [Full Text]

				W. T. Loging, A. Lal, I-M. Siu, T. L. Loney, C. J. Wikstrand, M. A. Marra, C. Prange, D. D. Bigner, R. L. Strausberg, and G. J. Riggins Identifying Potential Tumor Markers and Antigens by Database Mining and Rapid Expression Screening Genome Res., September 1, 2000; 10(9): 1393 - 1402. [Abstract] [Full Text]

				R. Thomas, L. D. True, J. A. Bassuk, P. H. Lange, and R. L. Vessella Differential Expression of Osteonectin/SPARC during Human Prostate Cancer Progression Clin. Cancer Res., March 1, 2000; 6(3): 1140 - 1149. [Abstract] [Full Text]

				S. A. Rempel, S. Dudas, S. Ge, and J. A. Gutiérrez Identification and Localization of the Cytokine SDF1 and Its Receptor, CXC Chemokine Receptor 4, to Regions of Necrosis and Angiogenesis in Human Glioblastoma Clin. Cancer Res., January 1, 2000; 6(1): 102 - 111. [Abstract] [Full Text]